Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for its lead […]

Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye

SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) — Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina, today announced that it has received a new grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the Company’s pioneering retinal tracer […]

Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) — Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases, announced today that they received a Phase 2A SBIR grant award from the National Institute on Aging of the National Institutes of Health (NIH). The grant award for over $1,500,000 […]

UPDATE – Amydis Awarded Prion Disease Grant from NIH

SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) — Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases, announced today that they received a grant award from The National Institute of Health (NIH) to develop a novel diagnostic for prion diseases. A prion, the name derived from […]

Amydis Receives Parkinson’s Disease Grant from Michael J. Fox Foundation

SAN DIEGO, July 10, 2018 (GLOBE NEWSWIRE) — Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases, announced today that they received a grant award from The Michael J. Fox Foundation for Parkinson’s Research. Amydis will explore the use of their platform technology to develop an […]

NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis

San Diego, CA, October 9, 2017: Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases, announced today that they received a Phase 1 SBIR grant award from the National Institute on Aging of the National Institutes of Health (NIH). The grant award for more than $530,000 […]

Amydis Named to San Diego Venture Groups (SDVG)

San Diego, CA, May 30, 2017: Amydis, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related disorders such as Alzheimer’s disease, today announced it has been named to the San Diego Venture Group’s (SDVG) 2017 Cool Companies list. The award honors the San Diego region’s leading technology […]

Amydis Awarded NIA-NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease

San Diego, CA, March 19, 2017: Amydis, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related neurodegenerative disorders such as Alzheimer’s disease, announced that they received a Phase 2 SBIR grant award by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). The […]

Amydis Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer’s disease

San Diego, CA, September 29, 2015: Amydis, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloidgenic protein-associated diseases, today announced a grant award by the National Institute of Aging (NIA), a center of the National Institute of Health (NIH). The grant award will fund research and development […]

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy

Latest Releases